About Us

Rea brings over 10 years of experience to the NanoCellect team. She spent 5 years as a bench scientist doing translational research on infectious disease and pandemic preparedness. Since then, Rea has held various commercial roles in reagent and instrumentation suppliers, including BioLegend, Immudex, and 10x Genomics. Rea received a Ph.D. in Microbiology & Cell Science and B.S. in Biology from the University of Florida.

Olivier brings over 20 years of experience in product development, product management and marketing in the biotech industry. As a research scientist, he worked in assay development using the GFP and developed several fluorescent protein variants for Clontech (now part of Takara). He acquired experience in bio-imaging at BD Biosciences and subsequently was part of the development and product management team for the Celigo image cytometer (now part of Nexcelom/PerkinElmer). Olivier leads the product management and marketing team at NanoCellect Biomedical. He received his PhD. in biochemistry from the University of Paris-Saclay and his MBA from the University California, San Diego.

After honing his Finance and Accounting chops over 2 decades, Aaron joined Nanocellect as Controller in November 2020.  Navigating multiple industries and company structures, Aaron had showcased his financial expertise across diverse business landscapes, but immediately felt at home with the innovative team at Nanocellect. Their entrepreneurial spirit and enthusiasm aligned perfectly with Aaron’s passion for building and improvement.  Known as “Coach” to the Wolfpack softball team, Aaron brings a positive leadership style that fosters teamwork and growth.  He earned a BS in Accounting from Azusa Pacific University and an MBA from The Ohio State University.

Peter Vander Horn brings to NanoCellect nearly three decades of proven experience in engineering and innovation within the biomedical sector. Throughout his career, Peter has consistently demonstrated a keen ability to bridge the gap between cutting-edge technology and practical applications. His arrival marks a significant step in reinforcing NanoCellect’s position as a driving force in the life science industry.

Wolfie graduated to Official NanoCellect Mascot shortly after the WOLF cell sorter was born. Since then, he has travelled the world, visited many customer labs, brought good spirit to scientists and success to their science. Wolfie favorite thing to say: “Gentle Sorting, Healthy Cells, Better Science”.

Mr. Nicolas Barthelemy has over 30 years of experience in the Biopharma, Life Sciences and Diagnostics sectors as an operating executive, Board Member and VC/PE advisor.  His 25 year operating experience involved scaling organizations and leading change across a broad range of functions (manufacturing, operations, commercial, general management), geographies and company sizes ($10M to $4B in revenue, both private and public).  Among his most recent operating roles were CEO at BioTheranostics and CCO at Life Technologies, where he was an executive for over 9 years. Prior to that, Mr. Barthelemy worked with Biogen and Merck. He currently serves on the board of directors of Repligen, Twist and Slingshot, and is Chairman of the Boards of NanoCellect and Biocare.  He previously served on the Boards of 908 Devices, Fluidigm, Genewiz, Avantor and Essen. Mr. Barthelemy received an M.S. in Chemical Engineering from the University of California, Berkeley, and an engineering degree from Ecole Supérieure de Physique et Chimie Industrielles (Paris, France).

Dr. Conley leads new investments for Paladin Capital Group while serving as an active Director on many of Paladin’s portfolio company Boards including NanoCellect Biomedical. Paul joined the Paladin team after more than 15 years of previous R&D and entrepreneurial experience. As founding CEO of BrightScale, he led the commercialization of a patented multi-core microprocessor technology in the HDTV market. As founding CEO of Appfluent Technology, he led the commercialization of patented in-memory distributed database technologies in the enterprise IT market. Prior to taking the entrepreneurial route, he spent nearly a decade in multidisciplinary R&D roles in the areas of high-performance computing, applied physics, and biomedical engineering, including postdoctoral positions at the Los Alamos National Laboratory. Paul earned a PhD in Computational Physics and an MS in Bioengineering from UCSD, as well as an MS and BS in Mechanical and Aerospace Engineering from the University of Virginia.

David Michael is an investor and advisor with nearly 30 years of international business experience. He co-founded Anzu Partners and developed the firm’s focus on breakthrough industrial technologies that shape and enable tomorrow’s industries. Prior to his work at Anzu, Mr. Michael spent 24 years at The Boston Consulting Group, where he was a Senior Partner and served in numerous leadership roles. He founded the firm’s Beijing office and led the firm’s Greater China practice, and then subsequently established the firm’s overall emerging markets practice. His other roles have included member of BCG’s Asia-Pacific and North American Management Teams and head of the Asia Technology practice. Mr. Michael has lived and worked in Beijing, Hong Kong, and Silicon Valley, and served clients in technology and life sciences across Asia and the Western U.S.

Mr. Michael has advised many of the world’s leading companies in the technology and life sciences sectors. His business networks across Asia and globally are extensive. He has served on the World Economic Forum’s Emerging Multinationals Council, the Strategy Board of China Mobile Corporation, and the US-China Business Council. He is on the International Advisory Board of the School of Global Policy at the University of California. Mr. Michael chaired the launch committee of the Ullens Center for Contemporary Art in Beijing, China, and founded the non-profit corporation Building Futures Now in East Palo Alto, CA.

Mr. Michael is the co-author of six articles in the Harvard Business Review, one MIT Sloan Management Review article, two business books, and has delivered a TED talk. Mr. Michael has an MBA from Stanford Business School, where he received the school’s highest honor, the Ernest Arbuckle Award. He earned his BA in Economics, magna cum laude, from Harvard University, and was a Rotary International Scholar at the Chinese University of Hong Kong.

Yuhwa Lo is a co-founder of NanoCellect.  He also holds the position of William SC Chang Endowed Chair and Distinguished Professor of Electrical and Computer Engineering Department at UCSD.  He is also affiliated with UCSD Materials Science and Engineering and Bioengineering Department.  Lo directs the UCSD San Diego Nanotechnology Infrastructure (SDNI), a national nanotechnology facility supported by the National Science Foundation.  His research interests cover the fields of biomedical devices and systems, Lab-on-chip, bioimaging, advanced semiconductor and photonics devices, and condensed matter physics and applications.  He has been awarded 50 patents and published over 500 scientific papers and been broadly involved in biotech and high-tech industries as consultants and scientific advisors.  He received his PhD in electrical and computer engineering from UC Berkeley.

Scott Estes has been with Codiak BioSciences since they began operations in 2016.  He has held several roles there focused on the development of the first scalable manufacturing process for engineered extracellular vesicles and the subsequent tech transfer to produce GMP material to support Codiak’s clinical programs.  Prior to joining Codiak, Scott had roles at both Biogen and Genzyme leading cell line development and analytical support for early process development.  Scott holds a PhD in Molecular and Cellular Biology from Roswell Park Cancer Institute and was a Post-Doctoral Fellow at the Massachusetts Institute of Technology.

Patricia Rogers has worked in the field of flow cytometry for the past sixteen years and has managed several flow cytometry cores, including Harvard Medical School/Harvard University.  She joined the Broad Institute of MIT and Harvard in 2015 to lead the newly founded flow cytometry core facility. The facility opened in 2016 and has evolved beyond flow to encompass single cell genomics, histology, and imaging.  Her philosophy for easy to use shared instrumentation has driven the approach of the Broad Flow Core to be one of the leading shared resource labs in Boston.  She has a Bachelor of Science from UMass Boston.

Dr. Stone is an award-winning immunologist with expertise in T cell immunology, immuno-oncology, and human immunology.  At GigaGen as Vice President of Oncology she leads immuno-oncology research and discovery of antibody therapies with best-in-class potential. Previously Dr. Stone was Assistant Professor at The Wistar Institute Cancer Center where her independent laboratory focused on understanding the multiple mechanisms of action of first-generation immune checkpoint inhibitorswith the goal of identifying strategies to overcome resistance. She was awarded several grants for her research including the Melanoma Research Alliance’s Bristol-Myers Squibb-MRA Young Investigator Award and funding from the NIH. She also held the position Wistar Institute Assistant Professor of Pathology and Laboratory Medicine at the Perlman School of Medicine at the University of Pennsylvania where she was a member of the Institute for Immunology, the Immunology Graduate Group Executive Committee, and the Gene Therapy and Vaccines Program. Dr. Stone is an active member of the American Association of Immunologists (AAI), where she serves as Chair of the AAI-Clinical Immunology Committee. Previously Dr. Stone served as an AAI’s Tumor

Immunology Abstract Programming Co-Chair, was an AAI Public Policy Fellow, and was the 2017 recipient of AAI’s Chambers-Thermo Fisher Scientific Memorial Award. Dr. Stone has published numerous manuscripts in journals including Immunity, Nature Reviews Immunology, Science, Cancer Immunology Research, ELife, and PNAS, mentored students and postdoctoral fellows, and served as a reviewer for study sections and journals. Dr. Stone holds a B.S. in Biology summa cum laude from the University of New Hampshire and a Ph.D. in Biological Sciences from UC-San Diego where she also completed a postdoctoral fellowship.